Adelaide scientists have uncovered a promising new biomarker and therapeutic target for ovarian cancer, offering a potential breakthrough in the fight against one of the deadliest gynaecological diseases worldwide. The discovery could significantly improve diagnosis, treatment, and survival rates for women affected by this aggressive cancer.
Ovarian cancer: A silent but lethal threat
Ovarian cancer remains the most lethal gynaecological malignancy globally, with dismal survival outcomes primarily due to late-stage diagnosis. Each year, more than 200,000 women lose their lives to ovarian cancer. Tragically, around 70% of cases are identified only after the disease has spread beyond the ovaries, making treatment less effective and recovery more difficult.
F2R: A new biomarker and treatment target
Researchers from the University of South Australia and the University of Adelaide have identified a cell surface receptor known as F2R (Protease-Activated Receptor 1) that may serve as both a diagnostic marker and therapeutic target. The findings, recently published in the International Journal of Molecular Sciences, could transform the clinical approach to ovarian cancer management.
Lead researcher Dr Hugo Albrecht from UniSA’s Centre for Pharmaceutical Innovation explains that F2R is frequently overexpressed in ovarian cancer tissues, especially among women whose cancer has become resistant to chemotherapy or spread to other organs. “This discovery represents a significant step forward,” Dr Albrecht stated. “Current biomarkers lack sensitivity and accuracy, leaving clinicians with few tools for early detection or for predicting treatment outcomes.”
Limitations of current diagnostic methods
Unlike other major cancers, ovarian cancer lacks a reliable screening method. The most commonly used biomarker, CA-125, can be elevated for reasons unrelated to cancer, such as benign ovarian cysts or inflammation. This limits its reliability for early or accurate diagnosis.
Compounding the problem, the early symptoms of ovarian cancer are often vague and non-specific — including abdominal bloating, indigestion, or urinary changes. These can easily be mistaken for common gastrointestinal or urinary disorders. As a result, many women receive a misdiagnosis or face significant delays in obtaining appropriate medical attention.
Advanced analysis reveals F2R’s diagnostic and prognostic potential
Dr Albrecht’s team conducted an extensive analysis of large genomic datasets and validated their findings using advanced imaging and tissue analysis techniques. They found that patients with higher levels of F2R expression had shorter survival times, confirming its potential role as a prognostic biomarker.
In laboratory studies using ovarian cancer cells, silencing F2R markedly reduced the ability of cancer cells to migrate, invade, and form spheroids—three critical processes involved in cancer metastasis. This indicates that F2R plays a key role in driving the spread of ovarian cancer within the body.
F2R inhibition boosts chemotherapy response
The researchers also discovered that when F2R activity was suppressed through drug-based inhibition, ovarian cancer cells became more sensitive to carboplatin, a widely used chemotherapy medication. This suggests that F2R-targeted therapies could enhance the effectiveness of existing treatment regimens and help overcome drug resistance—a major challenge in ovarian cancer care.
Toward more precise oncology treatments
Co-author Dr Carmela Ricciardelli from the University of Adelaide’s Robinson Research Institute emphasized that the findings open the door to more personalized and effective oncology strategies. “By testing for F2R expression levels, clinicians could better identify patients at risk of early recurrence or chemotherapy resistance,” she explained. “Moreover, we can design therapies that work synergistically with standard chemotherapy to deliver better outcomes.”
Next steps: Clinical validation and patient impact
While the research so far is based on preclinical studies, the team underscores the need for large-scale clinical validation to confirm F2R’s diagnostic and therapeutic potential. “Ovarian cancer has long been known as a silent killer because of our inability to detect it early and accurately,” said Dr Albrecht. “Our discovery of F2R’s central role in disease progression offers new hope. It provides a foundation for future diagnostic tests and targeted treatments that could genuinely improve survival rates.”
Global significance and research collaboration
The study, titled “Protease-activated receptor F2R is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer”, was conducted by a collaborative team from the University of South Australia, the University of Adelaide, and the Royal Adelaide Hospital. Their work represents a major step toward understanding how specific molecular mechanisms contribute to cancer metastasis and resistance, two of the biggest hurdles in modern oncology.
Related topics
